Literature DB >> 22310953

Vasculitis: the elusive optimal induction strategy for vasculitis.

JulieAnne G McGregor, Ronald J Falk.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22310953     DOI： 10.1038/nrneph.2012.16

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

1.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

2.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Authors:  Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

3.  Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.

Authors:  Lorraine Harper; Matthew D Morgan; Michael Walsh; Peter Hoglund; Kerstin Westman; Oliver Flossmann; Vladimir Tesar; Phillipe Vanhille; Kirsten de Groot; Raashid Luqmani; Luis Felipe Flores-Suarez; Richard Watts; Charles Pusey; Annette Bruchfeld; Niels Rasmussen; Daniel Blockmans; Caroline O Savage; David Jayne
Journal:  Ann Rheum Dis       Date:  2011-11-29       Impact factor: 19.103

4.  The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review.

Authors:  K de Groot; D Adu; C O Savage
Journal:  Nephrol Dial Transplant       Date:  2001-10       Impact factor: 5.992

5.  A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis.

Authors:  L Guillevin; J F Cordier; F Lhote; P Cohen; B Jarrousse; I Royer; P Lesavre; C Jacquot; P Bindi; P Bielefeld; J F Desson; F Détrée; A Dubois; E Hachulla; B Hoen; D Jacomy; C Seigneuric; D Lauque; M Stern; M Longy-Boursier
Journal:  Arthritis Rheum       Date:  1997-12

6.  Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis.

Authors:  Susan L Hogan; Ronald J Falk; Hyunsook Chin; Jianwen Cai; Caroline E Jennette; J Charles Jennette; Patrick H Nachman
Journal:  Ann Intern Med       Date:  2005-11-01       Impact factor: 25.391

7.  Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis.

Authors:  P H Nachman; S L Hogan; J C Jennette; R J Falk
Journal:  J Am Soc Nephrol       Date:  1996-01       Impact factor: 10.121

8.  Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis.

Authors:  Mark A Little; Peter Nightingale; C A Verburgh; Thomas Hauser; Kirsten De Groot; Caroline Savage; David Jayne; Lorraine Harper
Journal:  Ann Rheum Dis       Date:  2009-07-01       Impact factor: 19.103

9.  Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.

Authors:  Kirsten de Groot; Lorraine Harper; David R W Jayne; Luis Felipe Flores Suarez; Gina Gregorini; Wolfgang L Gross; Rashid Luqmani; Charles D Pusey; Niels Rasmussen; Renato A Sinico; Vladimir Tesar; Philippe Vanhille; Kerstin Westman; Caroline O S Savage
Journal:  Ann Intern Med       Date:  2009-05-19       Impact factor: 25.391

10.  Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts.

Authors:  Christian Pagnoux; Susan L Hogan; Hyunsook Chin; J Charles Jennette; Ronald J Falk; Loïc Guillevin; Patrick H Nachman
Journal:  Arthritis Rheum       Date:  2008-09
  10 in total
  3 in total

1.  Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  JulieAnne G McGregor; Susan L Hogan; Elizabeth S Kotzen; Caroline J Poulton; Yichun Hu; Roberto Negrete-Lopez; Jason M Kidd; Suzanne L Katsanos; Donna O Bunch; Patrick H Nachman; Ronald J Falk
Journal:  Nephrol Dial Transplant       Date:  2015-04       Impact factor: 5.992

2.  What Everybody is Doing but No One is Talking About: Use of Complementary and Alternative Medicine in the ANCA Associated Vasculitis Population.

Authors:  Elisabeth A B Berg; JulieAnne G McGregor; Madelyn E Burkart; Caroline J Poulton; Yichun Hu; Ronald J Falk; Susan L Hogan
Journal:  J Autoimmune Dis Rheumatol       Date:  2014-11-01

Review 3.  Avoidance of Harm From Treatment for ANCA-Associated Vasculitis.

Authors:  Catherine King; Lorraine Harper
Journal:  Curr Treatm Opt Rheumatol       Date:  2017-11-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.